Rizobacter and Marrone Bio Innovations Expand Strategic Alliance to Supply Novel Seed Treatment in Brazil
July 12 2021 - 8:00AM
Rizobacter -- a subsidiary of Bioceres Crop Solutions Corp. (NYSE:
BIOX) and a global leader in sustainable solutions for agriculture
-- and Marrone Bio (NASDAQ: MBII) (MBI) -- an international leader
in sustainable bioprotection and plant health solutions -- today
announced that Rizonema™, a biological seed treatment for nematodes
and soil dwelling insects, will be offered for use in row crops in
Brazil through an expanded distribution agreement.
Multiple regulatory trials in Brazil have proven the efficacy of
Rizonema on key nematode species in soybeans and corn. MBI will
continue conducting field trials in the 2021 growing season to
expand the product label for use in cotton and to include
additional nematodes and soil dwelling insects. During the
regulatory submission and review process, MBI and Rizobacter
agronomists will continue to educate Brazilian growers on the
benefits of biological seed treatments to sustainably control
yield-robbing pests.
Pending regulatory approvals, Rizonema could be commercially
available as early as the 2023 planting season.
“Rizobacter has made a long-term commitment to bring more
sustainable crop solutions to South American farmers, with no
compromise on performance,” said Ricardo Yapur, Rizobacter’s chief
executive officer. “Working with a biological leader such as MBI is
a great way two companies with common goals and complementary
expertise can make a lasting impact on farming practices. With this
alliance, growers will be able to improve yield and return on
investment while taking even greater care of the earth that
sustains us all.”
"Brazil is a key market for expansion as we grow globally with
our seed treatment solutions,” said MBI Chief Executive Officer
Kevin Helash. “In 2023, we are targeting to have 45% of our sales
from seed and soil treatments, and 20% of our sales in Latin
America. Rizobacter has decades of experience in the Latin American
market and is well established in the seed protection market. Their
reputation and infrastructure, combined with MBI’s biological
expertise and in-market presence, will provide growers and
distributors greater value by converting to a more sustainable
alternative.”
The estimated market size of seed treatments in Brazil is
expected to reach USD $1.27 billion by 2024. According to Mordor
Intelligence, seed treatments overall are projected to grow at an
8.5% compound annual growth rate (CAGR) between 2019 and 2024, with
biological options increasing at a faster pace with a projected
CAGR of 10.4%. Brazil is the world’s largest producer of soybeans,
and a leading producer of corn and cotton.
About RizobacterRizobacter, a subsidiary of
Bioceres Crop Solutions Corp. (NYSE: BIOX) is a leading company in
the development, manufacturing and commercialization of biological
solutions applied to agriculture. Rizobacter is delivering
state-of-the-art technologies in 31 countries through its eight
subsidiaries and highly-skilled distribution network. Rizobacter’s
main product lines are biologicals, adjuvants and specialty
fertilizers. Rizoliq TOP®, Osmium®, Signum®, Rizoliq LLI®,
Rizospray Extremo®, Rizospray Integrum® and Rizostar® are flagship
brands of Rizobacter.For additional information, visit the
company’s website at www.rizobacter.com or follow on social media:
Twitter, LinkedIn and Instagram.
Rizobacter Contact:Pedro Mac Mullen, Marketing
Directorpmacmullen@rizobacter.com.ar+54-2477-409400
About Marrone Bio InnovationsMarrone Bio
Innovations Inc. (NASDAQ: MBII) is a growth-oriented
agricultural company leading the movement to environmentally
sustainable farming practices through the discovery, development
and sale of innovative biological products for crop protection,
crop health and crop nutrition. Our portfolio of more than 15
products helps customers operate more sustainably while increasing
their return on investment. The company’s commercial products are
sold globally and supported by a robust portfolio of more than 500
issued and pending patents. Our end markets include row
crops; fruits and vegetables; trees, nuts and vines; and greenhouse
production. The Company’s research and development program uses
proprietary technologies to isolate and screen naturally occurring
microorganisms and plant extracts to create new, environmentally
sound solutions in agriculture. For more information, please visit
the Company’s website at marronebio.com.
Learn more about Marrone Bio Innovations
at www.marronebio.com. We also use our investor relations
website, https://investors.marronebio.com, as well as our
corporate Twitter account, @Marronebio, as means of disclosing
material non-public information, and encourage our investors and
others to monitor and review the information we make public in
these locations. Follow us on social
media: Twitter, LinkedIn and Instagram.
Marrone Bio Innovations Forward Looking
StatementsThis press release contains forward-looking
statements that involve substantial risks and uncertainties. All
statements, other than statements of historical facts, included in
this press release regarding strategy, future operations and plans,
including assumptions underlying such statements, are
forward-looking statements, and should not be relied upon as
representing MBI’s views as of any subsequent date. Such
forward-looking statements are based on information available to
the Company as of the date of this release and involve a number of
risks and uncertainties, some beyond the Company’s control, that
could cause actual results to differ materially from those
anticipated by these forward-looking statements, including, the
sales potential in South America, weather, the novel coronavirus
COVID-19 and supply chain interruptions due to COVID-19, regulatory
and other factors affecting demand for the MBI’s products, any
difficulty in marketing MBI’s products in its target markets,
competition in the market for pest management products, lack of
understanding of bio-based pest management products by customers
and growers. Additional information that could lead to material
changes in MBI’s performance is contained in its filings with the
SEC. MBI is under no obligation to, and expressly disclaims any
responsibility to, update or alter forward-looking statements
contained in this release, whether as a result of current
information, future events or otherwise.
Marrone Bio Innovations Contact:Clyde
Montevirgen, Vice President of New Business Development &
Investor Relationsinfo@marronebio.com 1-530-750-2800
Marrone Bio Innovations (NASDAQ:MBII)
Historical Stock Chart
From Jun 2024 to Jul 2024
Marrone Bio Innovations (NASDAQ:MBII)
Historical Stock Chart
From Jul 2023 to Jul 2024